Compare Philip Morris International Inc. (PM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Philip Morris International Inc. is far larger — about 4.1× Regeneron Pharmaceuticals Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| PM | REGN | |
|---|---|---|
Market Cap | $293.07B | $70.79B |
Sector | Consumer Staples | Health |
52-Week High | $192.98 | $812.27 |
52-Week Low | $144.33 | $545.46 |
Enterprise Value | $339.57B | $64.74B |
Dividend Yield | 3.13% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with strong analyst support (17 buy ratings) and a $194 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal robust profitability with 26.74% net margins and consistent revenue growth to $40.65B in 2025. Recent news includes a profit forecast revision due to a $500M impairment charge and CFO succession planning.
PM offers stable dividend income and brand strength but faces headwinds from cost pressures and illicit market growth. The stock trades at a premium valuation (P/E 27.13) with elevated debt levels, requiring monitoring of pricing power and regulatory developments. Near-term catalysts include Q2 earnings and execution of the smoke-free transition strategy.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
